Rep. Dingell oversight of CLIA
This article was originally published in The Gray Sheet
Executive SummaryStaffers from Rep. John Dingell's (D-Mich.) House Energy and Commerce oversight subcommittee plan to meet with Bruce Vladeck after he is confirmed as Health Care Financing Administration chief to discuss their concerns with implementation of the Clinical Laboratory Improvement Amendments of 1988. Concerns include FDA delays in reviewing quality control labeling and assigning complexity categorizations for tests and the slow pace of third-party accreditation by HCFA. Vladeck was nominated to lead HCFA on March 5 ("The Gray Sheet" March 8, p. 25).
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.